Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Provided By PR Newswire
Last update: Nov 5, 2024
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally –
Read more at prnewswire.com
